Study #2016-0614
A Pilot Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients with Surgically Accessible Recurrent/Progressive Glioblastoma
MD Anderson Study Status
Not Accepting
Treatment Agent
MK-3475
Description
This research study is studying an immunotherapy as a possible treatment for Glioblastoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Brain Cancer
Study phase:
Phase I
Physician name:
Nazanin Majd
Department:
Neuro-Oncology
For general questions about clinical trials:
1-877-421-1842
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.